Advanced Computing in the Age of AI | Tuesday, April 16, 2024

YarcData and Selventa Align for Personalized Medicine 

YarcData has recently announced that it will join together with the systems diagnostics company, Selventa, to bring big data to Selventa’s push for personalized medicine. Through the collaboration Selventa will have access to YarcData’s Urika analytics appliance, which will be used to help pharmaceutical companies accelerate drug discoveries as well as market delivery.

Urika is used in addition to existing hardware to break down data silos and support broader pattern-based searches that eliminates the wait time that would otherwise be used to consolidate partitioned databases.

“Selventa’s solution running on Urika will help pharmaceutical companies do what they have been trying to do on their own—build databases that enable new drug discoveries and speed time to market,” says Dave Anstey, global segment leader for Life Sciences at YarcData.

Selventa’s flagship product, called Systems Diagnostics (SysDx) is designed to take in biological information including genomic, epigenomic, and metabolic data, and combine them with information from electronic medical records to offer a comprehensive view both of a patient’s condition and how they are responding to treatment.

Currently, most databases are partitioned by disease to limit them to a manageable size for searching, but this also prevents researchers from identifying relationships between comorbid conditions, genetics, and various treatments. Selventa notes that this focus on a singular silo both limits traditional medical diagnostics and distinguishes it from SysDx.

“With 50 percent of drugs ineffective or worse, there is an immediate opportunity to better match treatments to individuals based on their biomarker profiles,” says Dave de Graaf, president and CEO of Selventa. “Using this insight, pharmaceutical companies can create a larger number of targeted products that optimally benefit patients.”

“Big data and the intellectual properties derived from it have an immense potential to drive personalized medicine,” de Graaf added. “This, in turn, will lead to an increase in knowledge and our requirements for scalable, flexible solutions that can deliver results in a fraction of the time than the traditional databases. In searching for a graph database solution, nothing compared to YarcData’s ability to pull all the data into one platform and one memory space to achieve the real-time speed and scalability.”